CorpDigest
Novartis AG
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-08 · By Swet Parvadiya
On October 4, 2023, Novartis completed the spin-off of Sandoz, its $10 billion generics division, and became a different company than it had been the day before. The spin-off eliminated an entire revenue category — high-volume, low-margin, price-competitive generics — and concentrated the remaining $54.5 billion in FY2025 net sales on patented medicines in oncology, immunology, cardiovascular disease, and neuroscience. The result is a 42.2% core operating income margin, one of the highest in the pharmaceutical industry, on a revenue base that is growing at double digits. The decision to exit generics was a rejection of diversification as a risk management strategy. Conventional pharmaceutical wisdom holds that a generics business provides revenue stability when patent cliffs erode branded drug sales. Novartis under CEO Vas Narasimhan bet the opposite: that capital concentrated in radioligand therapies, gene therapies, and targeted oncology drugs would generate better long-term returns than capital spread across a high-volume, low-differentiation generics portfolio. FY2025 results — $54.5 billion in net sales, $17.6 billion in free cash flow, and $13.97 billion in net income — suggest the bet is working. The radioligand therapy platform is Novartis's most technically distinctive asset. Pluvicto, a prostate cancer treatment that delivers targeted radiation directly to cancer cells by binding to a protein overexpressed in prostate tumors, generated $2.0 billion in FY2025 sales, a 42% increase at constant currency. The peak sales outlook exceeds $4 billion annually. The Advanced Accelerator Applications acquisition in 2018 and the Chinook Therapeutics and MorphoSys acquisitions in 2023 and 2024 respectively were the capital deployments that built and extended this platform. Entresto, the heart failure treatment explicitly named in Medicare price negotiation proceedings under the Inflation Reduction Act, represents the primary near-term revenue risk. US government negotiation of Medicare prices directly affects the drug's pricing power in Novartis's largest single market. How Novartis navigates Entresto's pricing trajectory — and whether Cosentyx, Kisqali, and Kesimpta can offset any revenue pressure — will largely determine whether the 42.2% operating margin holds through 2026.
Chief Executive Officer
Narasimhan executed the strategic spin-off of the Sandoz generics division in October 2023, transforming Novartis into a pure-play innovative medicines company. He has also overseen a significant portfolio optimization, divesting non-core assets and acquiring late-stage biotechs like Chinook and MorphoSys to strengthen the pipeline.
Chief Financial Officer
Kirsch managed the financial aspects of the Sandoz spin-off and the company's capital allocation strategy, including the $10 billion share buyback program. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition to a pure-play model.
Chief Scientific Officer
Tsai leads the company's global R&D organization, overseeing a $10.8 billion annual budget and a pipeline of over 200 clinical projects. He has been instrumental in advancing the radioligand therapy platform and expanding the company's presence in rare diseases and immunology.
Chief Digital and Technology Officer
Tansche is responsible for driving the company's digital transformation, including the use of artificial intelligence in drug discovery and the implementation of data analytics to optimize clinical trials and commercial operations.
This narrative of transformation, risk, and scientific ambition defines the modern Novartis, an organization that has successfully shed its industrial past to become a pure engine of medical innovation. Entresto was explicitly named in recent Medicare negotiation rounds, forcing Novartis to accept lower reimbursement rates or risk exclusion from the federal program. The competitive narrative in oncology is equally dynamic, with the rapid emergence of ADCs and bispecific antibodies threatening to displace traditional small molecule targeted therapies. The company's response to these challenges has been to pivot aggressively toward radioligand therapy and rare diseases, but this pivot requires massive capital expenditure and carries high binary risk.
The supply chain constraints for radioligand therapies present another significant operational challenge. To mitigate this risk, Novartis has invested in the construction of its own isotope production facilities and has secured long-term supply agreements with multiple vendors, but the fundamental vulnerability of the supply chain remains a critical challenge that requires constant monitoring and contingency planning. However, this optimistic outlook is contingent on the successful navigation of several key risks, including the potential for clinical trial failures, increased regulatory pricing pressure in the US and Europe, and the continued threat of generic competition for remaining legacy assets.
Novartis has had three CEOs since its 1996 founding. Daniel Vasella served as the founding CEO from December 1996 through January 2010 — a fourteen-year tenure that established the company's strategic structure, including the agribusiness spin-off (2000), the Chiron acquisition (2006), and the multi-stage Alcon acquisition (2008-2011). Joseph Jimenez, a former H. J. Heinz and ConAgra executive who joined Novartis in 2007 as head of consumer health and later head of pharmaceuticals, served as CEO from February 2010 through January 2018. Jimenez's tenure included completion of the Alcon acquisition, the 2015 asset swap with GSK that exchanged Novartis's vaccines (excluding influenza) and consumer-health businesses for GSK's oncology portfolio (creating major new oncology medicines including Tafinlar+Mekinist), and the 2015 sale of Novartis's animal-health business to Eli Lilly for $5.4 billion. Vas Narasimhan succeeded Jimenez in February 2018 and has been CEO continuously since. Each transition has been planned with a 6-12 month CEO-designate period, and outgoing CEOs have typically stepped fully out of operating roles rather than continuing as Chair. The transitions have been smooth and reflect the Swiss corporate-governance preference for orderly succession with independent Chair oversight.
Joseph Jimenez led Novartis from February 2010 through January 2018 with a stated priority of refocusing the company on innovative pharmaceuticals while completing the Alcon integration. The signature strategic action of his tenure was the April 2014 portfolio reshaping in partnership with GSK and Eli Lilly. Novartis sold its animal-health business to Lilly for $5.4 billion. Novartis sold its vaccines business (excluding influenza) to GSK for $7.1 billion. GSK sold its oncology business to Novartis for $14.5 billion (which brought Tafinlar, Mekinist, Promacta, Votrient, and other established oncology medicines into Novartis). The vaccines-for-oncology asset swap with GSK created two pure-play businesses where each company gained scale: Novartis as a leader in oncology and GSK as a leader in vaccines. Jimenez also oversaw the launches of Cosentyx (2015) and Entresto (2015), both of which became multi-billion-dollar medicines. Operating margin was rebuilt from low-30s percent to mid-30s percent across his tenure. Capital return through dividends and buybacks was steady. Jimenez was criticized by some analysts for slow pipeline output during the middle of his tenure, with the 2015-2016 period producing few major new approvals, but the Cosentyx and Entresto launches and the GSK asset swap leave a durable strategic legacy.
Vasant "Vas" Narasimhan became CEO of Novartis on February 1, 2018, succeeding Joseph Jimenez. A trained physician (Harvard MD) and public-health expert (Harvard MPH) who joined Novartis in 2005, Narasimhan had previously been Global Head of Drug Development and Chief Medical Officer before becoming CEO at age 41 — one of the youngest CEOs of a large-cap pharma. His tenure has been defined by four priorities. First, portfolio simplification: he completed the Alcon spin-off (April 2019) and the Sandoz spin-off (October 2023), transforming Novartis into a pure-play innovative-medicines company. Second, pipeline acquisitions: AveXis ($8.7B 2018), Endocyte ($2.1B 2018), The Medicines Company ($9.7B 2020), Chinook Therapeutics ($3.5B 2023), and MorphoSys ($2.9B 2024) supplemented internal R&D. Third, data-and-digital transformation: investments in clinical-trial digitization, AI-driven drug discovery, and operational analytics aimed at improving R&D productivity. Fourth, therapeutic-area focus on the five priorities (cardiovascular/renal/metabolic, immunology, neuroscience, oncology, hematology) rather than broad horizontal pipeline coverage. Under Narasimhan, Novartis's continuing-operations revenue grew from approximately $42 billion (2019 pro-forma) to $50.3 billion in 2024 with operating margin expanding from 27% to 34%, and the share price has materially outperformed European pharma peers through 2024-2025.
Novartis under Vas Narasimhan operates with an executive committee that includes functional leaders and business-unit heads reporting directly to the CEO. As of 2024-2025, key members include Harry Kirsch as Chief Financial Officer (joined 2013, previously head of pharma finance), Shreeram Aradhye as President of Global Drug Development and Chief Medical Officer, Robert Weltevreden as Head of Novartis Business Services, Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer, and presidents of the major regional and operating units (US, International, Innovative Medicines). The Chair is Joerg Reinhardt, who has served since 2013 and provides board-level continuity. The structure is intentionally lean for a company of Novartis's scale (approximately 75,000 employees), with the Sandoz spin-off having removed roughly 20,000 employees and the Alcon spin-off having removed roughly 22,000 in 2019. The Innovative Medicines business is organized into International and US units (with US as the largest single market), and the manufacturing footprint includes Basel, multiple European sites, US sites in New Jersey, North Carolina, and Indianapolis, and select Asian sites. The R&D organization, NIBR (Novartis Institutes for Biomedical Research), is headquartered in Cambridge, Massachusetts and operates as the global discovery-research organization complementing therapeutic-area development teams.